TWI692485B - 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途 - Google Patents

抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途 Download PDF

Info

Publication number
TWI692485B
TWI692485B TW107143050A TW107143050A TWI692485B TW I692485 B TWI692485 B TW I692485B TW 107143050 A TW107143050 A TW 107143050A TW 107143050 A TW107143050 A TW 107143050A TW I692485 B TWI692485 B TW I692485B
Authority
TW
Taiwan
Prior art keywords
identification number
sequence identification
sequence
cgrp
present
Prior art date
Application number
TW107143050A
Other languages
English (en)
Chinese (zh)
Other versions
TW201936642A (zh
Inventor
布萊恩Ｒ 柯法席維屈
凱提 歐爾生
班傑明Ｈ 杜薩
珍斯Ｊ 比爾葛林
約翰Ａ 雷特漢
丹妮爾Ｍ 米歇爾
派翠西亞Ｄ 麥克尼爾
妮可Ｍ 詹生
馬帝茲 李奧Ｆ 賈西亞
瑪麗亞 克里斯蒂娜 盧米斯
Original Assignee
美商艾爾德生物控股有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47175055&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI692485(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商艾爾德生物控股有限責任公司 filed Critical 美商艾爾德生物控股有限責任公司
Publication of TW201936642A publication Critical patent/TW201936642A/zh
Application granted granted Critical
Publication of TWI692485B publication Critical patent/TWI692485B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW107143050A 2011-05-20 2012-05-21 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途 TWI692485B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161488660P 2011-05-20 2011-05-20
US61/488,660 2011-05-20

Publications (2)

Publication Number Publication Date
TW201936642A TW201936642A (zh) 2019-09-16
TWI692485B true TWI692485B (zh) 2020-05-01

Family

ID=47175055

Family Applications (4)

Application Number Title Priority Date Filing Date
TW101118029A TWI646111B (zh) 2011-05-20 2012-05-21 抗降血鈣素基因相關胜肽（ａｎｔｉ－ｃｇｒｐ）組成物及其用途
TW106121803A TWI685505B (zh) 2011-05-20 2012-05-21 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途
TW107143050A TWI692485B (zh) 2011-05-20 2012-05-21 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途
TW109110803A TWI719869B (zh) 2011-05-20 2012-05-21 抗降血鈣素基因相關胜肽(anti-cgrp)組成物及其用途

Family Applications Before (2)

Application Number Title Priority Date Filing Date
TW101118029A TWI646111B (zh) 2011-05-20 2012-05-21 抗降血鈣素基因相關胜肽（ａｎｔｉ－ｃｇｒｐ）組成物及其用途
TW106121803A TWI685505B (zh) 2011-05-20 2012-05-21 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW109110803A TWI719869B (zh) 2011-05-20 2012-05-21 抗降血鈣素基因相關胜肽(anti-cgrp)組成物及其用途

Country Status (38)

Country Link
US (10) US9745373B2 (enExample)
EP (5) EP2710039B1 (enExample)
JP (3) JP6282584B2 (enExample)
KR (1) KR102128627B1 (enExample)
CN (5) CN107602700B (enExample)
AP (1) AP2013007259A0 (enExample)
AR (3) AR086516A1 (enExample)
AU (3) AU2012258966C1 (enExample)
BR (2) BR112013029932A2 (enExample)
CA (3) CA2836649C (enExample)
CL (3) CL2013003336A1 (enExample)
CO (1) CO6870005A2 (enExample)
CY (2) CY1124209T1 (enExample)
DK (3) DK3662932T3 (enExample)
EA (3) EA201891284A1 (enExample)
ES (3) ES2873837T3 (enExample)
FR (1) FR22C1032I2 (enExample)
HR (3) HRP20190640T1 (enExample)
HU (4) HUE055505T2 (enExample)
IL (4) IL229431B (enExample)
LT (4) LT2710039T (enExample)
LU (1) LUC00270I2 (enExample)
MX (3) MX370749B (enExample)
NL (1) NL301181I2 (enExample)
NO (1) NO2022029I1 (enExample)
NZ (1) NZ733060A (enExample)
PE (2) PE20180502A1 (enExample)
PH (2) PH12013502405B1 (enExample)
PL (3) PL3495392T3 (enExample)
PT (3) PT3495392T (enExample)
RS (3) RS62306B1 (enExample)
SG (2) SG194938A1 (enExample)
SI (3) SI3495392T1 (enExample)
SM (3) SMT202100526T1 (enExample)
TR (1) TR201904088T4 (enExample)
TW (4) TWI646111B (enExample)
WO (1) WO2012162243A2 (enExample)
ZA (1) ZA201308637B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI719869B (zh) * 2011-05-20 2021-02-21 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽(anti-cgrp)組成物及其用途

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20080200A (sr) 2005-11-14 2009-07-15 Rinat Neuroscience Corp., Antagonistička antitela usmerena protiv kalcitonina, peptida povezanog sa genom, i postupak njihovog korišćenja
US8293239B2 (en) 2008-03-04 2012-10-23 Pfizer Limited Methods of treating chronic pain
NZ717704A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
DK2709663T3 (da) 2011-05-20 2019-05-20 Alderbio Holdings Llc Anvendelse af anti-CGRP-antistoffer og antistoffragmenter til forebyggelse eller inhibering af fotofobi eller aversion mod lys hos individer med behov herfor, især migrænikere
AR095615A1 (es) 2013-03-15 2015-10-28 Alder Biopharmaceuticals Inc Purificación de anticuerpos y monitoreo de pureza
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US20150017166A1 (en) * 2013-07-03 2015-01-15 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CN111973740A (zh) 2014-03-21 2020-11-24 泰华制药国际有限公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
CA2983030A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
EA201890578A1 (ru) * 2015-09-24 2018-12-28 Тева Фармасьютикалз Интернэшнл Гмбх Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли
TW201725212A (zh) * 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2017132062A1 (en) * 2016-01-28 2017-08-03 Eli Lilly And Company Cgrp antibodies and uses thereof
EP3411066A1 (en) 2016-02-01 2018-12-12 Eli Lilly and Company Parathyroid hormone anti-rankl antibody fusion compounds
MX2018012470A (es) 2016-04-15 2019-07-01 Alder Biopharmaceuticals Inc Anticuerpos anti pacap humanizados y usos de ellos.
KR20190067181A (ko) 2016-09-23 2019-06-14 테바 파마슈티컬스 인터내셔널 게엠베하 군발성 두통의 치료
CN109952314A (zh) 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
MX2019010397A (es) 2017-03-02 2020-08-20 Beth Israel Deaconess Medical Ct Inc Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina.
JP2020517644A (ja) * 2017-04-19 2020-06-18 マンセル、ジョン 疼痛障害の治療のための組成物および方法
US10738110B2 (en) 2018-01-12 2020-08-11 Amgen Inc. PAC1 antibodies and uses thereof
US11274158B2 (en) * 2018-01-30 2022-03-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
JP2021518748A (ja) * 2018-02-23 2021-08-05 アールイーエムディー バイオセラピューティクス，インコーポレイテッドＲＥＭＤ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ カルシトニン遺伝子関連ペプチド（ｃｇｒｐ）アンタゴニスト抗体
WO2019231800A1 (en) * 2018-05-31 2019-12-05 Eli Lilly And Company Anti-cgrp antibodies for treating menstrual-related migraines
US10899826B1 (en) * 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
EP3674418A1 (en) * 2018-12-26 2020-07-01 Life Length S.L. Method for measuring telomere associated variables and uses thereof for the diagnosis and/or prognosis of telomeric-associated diseases
KR20210113597A (ko) 2019-01-08 2021-09-16 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용한 두통의 급성 치료 및 신속 치료
MA54709A (fr) * 2019-01-08 2022-04-13 H Lundbeck As Traitement de maux de tête dus à un usage abusif de médicaments à l'aide d'anticorps anti-cgrp ou anti-cgrp-r
BR112021016996A8 (pt) * 2019-02-28 2022-11-22 Dandi Bioscience Inc Polipeptídeo com atividade antibacteriana, composição para prevenir ou tratar sepsis compreendendo a mesma e composição antibacteriana
JP2022533030A (ja) * 2019-05-02 2022-07-21 ハー・ルンドベック・アクチエゼルスカベット 抗ｃｇｒｐ抗体を用いた頭痛の治療
WO2020239014A1 (zh) * 2019-05-30 2020-12-03 山东博安生物技术有限公司 抗cgrp抗体及其应用
KR20210124867A (ko) 2020-04-06 2021-10-15 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료
KR20230157986A (ko) 2021-03-02 2023-11-17 체게에르페 다이어그노스틱스 게엠베하 편투통 발생의 치료 및/또는 저감
US20250109188A1 (en) 2021-08-24 2025-04-03 Cgrp Diagnostics Gmbh Preventative treatment of migraine
IL310885A (en) 2021-08-27 2024-04-01 H Lundbeck As Treatment of cluster headache using anti-CGRP antibodies
CA3243636A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg CONJUGATED COMPRISING AT LEAST ONE β-GLUCANE OR ONE MANNANA
WO2024032750A1 (zh) * 2022-08-11 2024-02-15 上海君实生物医药科技股份有限公司 抗cgrp抗体及用途
IT202300010371A1 (it) * 2023-05-23 2024-11-23 Alberto Chiarugi Inibitori della crescita tumorale
CN120899912A (zh) * 2024-05-07 2025-11-07 中国人民解放军军事科学院军事医学研究院 一种治疗自身免疫性疾病的方法和应用
CN118271438B (zh) * 2024-05-27 2024-08-30 上海宏成药业有限公司 抗cgrp抗体或其抗原结合片段及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007076336A1 (en) * 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3662333A (en) 1970-09-08 1972-05-09 Bendix Corp Hydraulic accumulator charge detector and indicating system
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5123197A (ja) 1974-08-21 1976-02-24 Hitachi Ltd Purosesugasukuromatogurafuno ondoseigyohoshiki
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3484377D1 (de) * 1983-06-15 1991-05-08 Celltech Ltd Peptide, pharmazeutische zusammensetzungen, gene, vektoren, wirtorganismen, verfahren zu deren herstellung und diagnostische reagenzien.
JPS62129297A (ja) 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5266561A (en) 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5364841A (en) 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
FR2669336B1 (fr) 1990-11-20 1993-01-22 Adir Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE4227454C1 (de) * 1992-08-19 1994-02-03 Henning Berlin Gmbh Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
WO1994021293A1 (en) 1993-03-19 1994-09-29 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5475995A (en) 1994-05-16 1995-12-19 Livingston; George G. Truck spare tire locking rod
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
ATE306930T1 (de) 1994-08-12 2005-11-15 Immunomedics Inc Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
JPH10504457A (ja) 1994-08-16 1998-05-06 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド カルシトニンレセプター
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
EP0851759A4 (en) 1995-09-05 2000-12-06 Smithkline Beecham Corp COMPOUNDS AND RELATED METHODS
US5710024A (en) * 1996-07-23 1998-01-20 Smithkline Beecham Corporation Polynucleotides that encode the calcitonin gene-related peptide receptor coponent factor (HOUNDC44)
JP2002511836A (ja) 1996-09-09 2002-04-16 スミスクライン・ビーチャム・コーポレイション 化合物および方法
CA2262818A1 (en) 1996-09-10 1998-03-19 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Modified amino acids, pharmaceuticals containing these compounds and methods for their production
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
WO1998056779A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
AU6211499A (en) 1998-09-30 2000-04-17 Merck & Co., Inc. Benzimidazolinyl piperidines as cgrp ligands
US20010036647A1 (en) 1998-10-22 2001-11-01 Prabhakara V. Choudary Functionally assembled antigen-specific intact recombinant antibody and a method for production thereof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1031350A1 (en) 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
US6521609B1 (en) 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
WO2001022972A2 (en) 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
CA2401652A1 (en) 2000-03-01 2001-09-07 Medimmune, Inc. High potency recombinant antibodies and method for producing them
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
US20020162125A1 (en) 2001-03-06 2002-10-31 Anne-Marie Salmon Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal
US20030181462A1 (en) 2001-08-17 2003-09-25 Boehringer Ingelheim Pharma Kg Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
WO2003045424A1 (en) 2001-11-26 2003-06-05 Protemix Corporation Limited Methods of compositions for normalizing lipid levels in mammalian tissues
DK1527100T3 (da) 2002-03-29 2009-09-07 Schering Corp Humane monoklonale antistoffer mod interleukin-5 og fremgangsm der og sammens tninger omfattende samme
EP1501929B1 (de) 2002-05-06 2013-03-27 Noxxon Pharma AG Cgrp bindende nukleinsäuren
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
MXPA04011960A (es) 2002-06-05 2005-03-31 Squibb Bristol Myers Co Antagonistas de receptores de peptidos relacionados con el gen de calcitonina.
EP2135879A3 (en) 2002-06-28 2010-06-23 Domantis Limited Ligand
PL375536A1 (en) * 2002-08-12 2005-11-28 Birkir Sveinsson Use of cgrp antagonist compounds for treatment of psoriasis
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1578799B8 (en) 2002-12-02 2011-03-23 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
EA011479B1 (ru) 2002-12-24 2009-04-28 Ринат Ньюросайенс Корп. Антитело связывающееся с ngf, и способы его применения
EP1606286B1 (en) 2003-03-14 2011-05-11 Merck Sharp & Dohme Corp. Benodiazepine spirohydantoin cgrp receptor antagonists
JP4673296B2 (ja) 2003-03-14 2011-04-20 メルク・シャープ・エンド・ドーム・コーポレイション アリールスピロヒダントインｃｇｒｐ受容体拮抗物質
WO2004083187A1 (en) 2003-03-14 2004-09-30 Merck & Co. Inc. Monocyclic anilide spirohydantoin cgrp receptor antagonists
CA2518830A1 (en) 2003-03-14 2004-09-30 Merck & Co., Inc. Carboxamide spirohydantoin cgrp receptor antagonists
US7202251B2 (en) 2003-03-14 2007-04-10 Merck & Co., Inc. Bicyclic anilide spirohydantoin CGRP receptor antagonists
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
CA2522024A1 (en) 2003-04-15 2004-10-28 Merck & Co., Inc. Cgrp receptor antagonists
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
EP1646611A1 (en) 2003-07-15 2006-04-19 Merck & Co., Inc. Hydroxypyridine cgrp receptor antagonists
NZ547279A (en) * 2003-10-22 2008-04-30 Keck Graduate Inst Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
US20080070239A1 (en) 2003-10-29 2008-03-20 University Of Rochester Detection of neureopeptides associated with pelvic pain disorders and uses thereof
CA2552757A1 (en) 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods of using cgrp for cardiovascular and renal indications
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en) 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004018794A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
TWI432196B (zh) 2005-01-18 2014-04-01 Euro Celtique Sa 內臟痛的治療
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
CA2619856A1 (en) 2005-08-25 2007-03-01 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US20070108378A1 (en) 2005-11-14 2007-05-17 Toru Terabayashi High pressure optical cell for a downhole optical fluid analyzer
RS20080200A (sr) 2005-11-14 2009-07-15 Rinat Neuroscience Corp., Antagonistička antitela usmerena protiv kalcitonina, peptida povezanog sa genom, i postupak njihovog korišćenja
ATE493412T1 (de) 2005-11-18 2011-01-15 Merck Sharp & Dohme Spirohydantoin-aryl-cgrp-rezeptorantagonisten
US9074352B2 (en) 2006-03-27 2015-07-07 John R. Ramun Universal control scheme for mobile hydraulic equipment and method for achieving the same
EP2021463B1 (en) 2006-05-19 2016-11-23 Alder Biopharmaceuticals, Inc. Culture method for obtaining a clonal population of antigen-specific b cells
EA200802381A1 (ru) 2006-06-08 2009-06-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение желудочно-кишечных расстройств антагонистами cgrp-пептида
ES2343481T3 (es) 2006-07-21 2010-08-02 Vertex Pharmaceuticals, Inc. Antagonistas del receptor cgrp.
US8075902B2 (en) * 2007-01-03 2011-12-13 Michael Powell Diagnosis and treatment of cancer related to human dormancy
CN105001332B (zh) 2007-05-21 2018-12-04 奥尔德生物控股有限责任公司 针对il-6的抗体及其用途
EP2162469A4 (en) 2007-05-21 2012-08-01 Alderbio Holdings Llc NEW METHODS OF HUMANIZING RABBIT ANTIBODIES AND HUMANIZED RABBIT ANTIBODIES
US9056905B2 (en) 2007-05-21 2015-06-16 Alderbio Holdings Llc Antibodies to TNF-α and use thereof
GB0725103D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Novel compounds
US8293239B2 (en) 2008-03-04 2012-10-23 Pfizer Limited Methods of treating chronic pain
US8298536B2 (en) 2008-03-04 2012-10-30 Pfizer Limited Methods of treating inflammatory pain
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
CN107441487B (zh) 2009-08-28 2021-09-14 泰华制药国际有限公司 通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法
JO3330B1 (ar) 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
US11214610B2 (en) * 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
TR201904088T4 (tr) * 2011-05-20 2019-05-21 Alderbio Holdings Llc Anti-CGRP bileşimleri ve bunların kullanımları.
DK2709663T3 (da) 2011-05-20 2019-05-20 Alderbio Holdings Llc Anvendelse af anti-CGRP-antistoffer og antistoffragmenter til forebyggelse eller inhibering af fotofobi eller aversion mod lys hos individer med behov herfor, især migrænikere
NZ717704A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
EA201890578A1 (ru) 2015-09-24 2018-12-28 Тева Фармасьютикалз Интернэшнл Гмбх Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли
MX2019010397A (es) * 2017-03-02 2020-08-20 Beth Israel Deaconess Medical Ct Inc Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina.
US11752099B2 (en) * 2017-03-27 2023-09-12 W. L. Gore & Associates, Inc. Injectable and biodegradable polymer formulations for controlled release of bioactive agents
WO2018236873A1 (en) * 2017-06-19 2018-12-27 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
MA54709A (fr) 2019-01-08 2022-04-13 H Lundbeck As Traitement de maux de tête dus à un usage abusif de médicaments à l'aide d'anticorps anti-cgrp ou anti-cgrp-r
KR20210113597A (ko) * 2019-01-08 2021-09-16 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용한 두통의 급성 치료 및 신속 치료

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007076336A1 (en) * 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI719869B (zh) * 2011-05-20 2021-02-21 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽(anti-cgrp)組成物及其用途

Also Published As

Publication number Publication date
US11111289B2 (en) 2021-09-07
CO6870005A2 (es) 2014-02-20
ES2873837T3 (es) 2021-11-04
IL229431A0 (en) 2014-01-30
PH12013502405A1 (en) 2014-02-10
AU2012258966C1 (en) 2022-02-03
PT3495392T (pt) 2021-09-22
AU2019226231B2 (en) 2021-06-03
TW201936642A (zh) 2019-09-16
EP3875115A1 (en) 2021-09-08
CN103748111A (zh) 2014-04-23
HUE044062T2 (hu) 2019-09-30
NL301181I2 (nl) 2022-11-24
TWI685505B (zh) 2020-02-21
CL2013003336A1 (es) 2014-06-06
RS62306B1 (sr) 2021-09-30
AU2017203890B2 (en) 2019-06-06
AP2013007259A0 (en) 2013-11-30
BR112013029932A2 (pt) 2017-01-31
TWI719869B (zh) 2021-02-21
CL2018001452A1 (es) 2018-08-10
TW202033559A (zh) 2020-09-16
CN107586338B (zh) 2021-09-17
US10214582B2 (en) 2019-02-26
US20180215813A1 (en) 2018-08-02
CA3079978A1 (en) 2012-11-29
US20180215814A1 (en) 2018-08-02
SG194938A1 (en) 2013-12-30
PH12013502405B1 (en) 2018-11-07
EA201592042A1 (ru) 2016-03-31
HRP20190640T1 (hr) 2019-05-31
JP2019150044A (ja) 2019-09-12
EA039905B1 (ru) 2022-03-25
JP2014517699A (ja) 2014-07-24
IL268464A (en) 2019-09-26
EA201301295A1 (ru) 2014-04-30
IL229431B (en) 2018-10-31
DK2710039T3 (en) 2019-04-01
CN107586338A (zh) 2018-01-16
EP2710039A4 (en) 2014-11-19
LT3662932T (lt) 2021-06-10
IL261927A (en) 2018-10-31
DK3662932T3 (da) 2021-05-17
TR201904088T4 (tr) 2019-05-21
CL2017001379A1 (es) 2017-12-29
EP3662932B1 (en) 2021-04-07
LTPA2022511I1 (enExample) 2022-07-11
PL3495392T3 (pl) 2021-12-13
NZ717570A (en) 2018-09-28
HUS2200031I1 (hu) 2022-07-28
US20240174738A1 (en) 2024-05-30
CN108424452A (zh) 2018-08-21
NO2022029I1 (no) 2022-07-08
AU2012258966B2 (en) 2017-03-09
SI3495392T1 (sl) 2021-11-30
SMT202100274T1 (it) 2021-07-12
IL270382B (en) 2020-11-30
NZ733060A (en) 2022-08-26
CN107602700B (zh) 2021-12-17
SI2710039T1 (sl) 2019-05-31
MX2019015745A (es) 2020-02-13
SI3662932T1 (sl) 2021-08-31
TW201811835A (zh) 2018-04-01
SMT201900293T1 (it) 2019-07-11
US20170174754A1 (en) 2017-06-22
TW201300419A (zh) 2013-01-01
US10066009B2 (en) 2018-09-04
KR102128627B1 (ko) 2020-06-30
AR118605A2 (es) 2021-10-20
EP3495392B1 (en) 2021-08-18
MX370749B (es) 2019-12-20
EP3495392A1 (en) 2019-06-12
LT3495392T (lt) 2021-09-27
AR086516A1 (es) 2013-12-18
US10189895B2 (en) 2019-01-29
AR123876A2 (es) 2023-01-18
PH12018500521A1 (en) 2019-04-15
KR20140042819A (ko) 2014-04-07
JP6282584B2 (ja) 2018-02-21
US10533048B2 (en) 2020-01-14
CA3080000A1 (en) 2012-11-29
RS58621B1 (sr) 2019-05-31
NL301181I1 (enExample) 2022-06-15
EA031065B1 (ru) 2018-11-30
AU2017203890A1 (en) 2017-06-29
MX2019008185A (es) 2019-09-09
JP2018038391A (ja) 2018-03-15
CY1124209T1 (el) 2022-05-27
PT3662932T (pt) 2021-05-14
PL2710039T3 (pl) 2019-07-31
LTC3495392I2 (enExample) 2024-12-10
HRP20211395T1 (hr) 2021-12-10
PE20180502A1 (es) 2018-03-09
NZ618637A (en) 2016-03-31
ZA201308637B (en) 2022-11-30
EP2710039A2 (en) 2014-03-26
US20120294797A1 (en) 2012-11-22
US10208112B2 (en) 2019-02-19
HUE055505T2 (hu) 2021-11-29
CN107602700A (zh) 2018-01-19
EA201891284A1 (ru) 2018-11-30
EP2710039B1 (en) 2019-01-09
WO2012162243A2 (en) 2012-11-29
LT2710039T (lt) 2019-04-25
FR22C1032I2 (fr) 2023-06-02
PL3662932T3 (pl) 2021-09-06
EP3662932A1 (en) 2020-06-10
IL261927B (en) 2019-11-28
US9745373B2 (en) 2017-08-29
FR22C1032I1 (fr) 2022-09-09
WO2012162243A3 (en) 2013-01-17
CN108373502B (zh) 2022-03-22
US20180215816A1 (en) 2018-08-02
CA2836649A1 (en) 2012-11-29
JP6952736B2 (ja) 2021-10-20
TWI646111B (zh) 2019-01-01
US20210047391A1 (en) 2021-02-18
BR122022012930B1 (pt) 2023-10-10
PT2710039T (pt) 2019-04-23
LUC00270I2 (enExample) 2025-04-25
CA2836649C (en) 2020-06-23
CY1124515T1 (el) 2022-07-22
SG10201604040PA (en) 2016-07-28
CN108424452B (zh) 2021-08-03
EP4115905A1 (en) 2023-01-11
DK3495392T3 (da) 2021-09-13
HRP20210777T1 (hr) 2021-06-25
ES2893073T3 (es) 2022-02-07
IL268464B (en) 2020-10-29
ES2715001T3 (es) 2019-05-31
CN103748111B (zh) 2018-04-27
AU2019226231A1 (en) 2019-09-26
US10179809B2 (en) 2019-01-15
US20190211085A1 (en) 2019-07-11
MX2013013535A (es) 2015-08-20
CN108373502A (zh) 2018-08-07
SMT202100526T1 (it) 2021-11-12
RS61793B1 (sr) 2021-06-30
PE20141787A1 (es) 2014-12-07
US20180215815A1 (en) 2018-08-02
HUE054437T2 (hu) 2021-09-28
US20190092842A1 (en) 2019-03-28
JP6527563B2 (ja) 2019-06-05

Similar Documents

Publication Publication Date Title
TWI692485B (zh) 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途
HK40055862A (en) Anti-cgrp compositions and use thereof
HK40084193A (en) Anti-cgrp compositions and use thereof
HK40029921B (en) Anti-cgrp compositions and use thereof
HK40029921A (en) Anti-cgrp compositions and use thereof
HK40009778B (en) Anti-cgrp compositions and use thereof
HK40009778A (en) Anti-cgrp compositions and use thereof
HK1196829B (en) Anti-cgrp compositions and use thereof
HK1196829A (en) Anti-cgrp compositions and use thereof
NZ717570B2 (en) Anti-cgrp compositions and use thereof